These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 15555834)
1. Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae. Plouffe JF; Martin DR Infect Dis Clin North Am; 2004 Dec; 18(4):963-74; x-xi. PubMed ID: 15555834 [TBL] [Abstract][Full Text] [Related]
2. Severe pneumococcal pneumonia: new strategies for management. Chiou CC; Yu VL Curr Opin Crit Care; 2006 Oct; 12(5):470-6. PubMed ID: 16943728 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis. De la Calle C; Ternavasio-de la Vega HG; Morata L; Marco F; Cardozo C; García-Vidal C; Del Rio A; Cilloniz C; Torres A; Martínez JA; Mensa J; Soriano A J Infect; 2018 Apr; 76(4):342-347. PubMed ID: 29360520 [TBL] [Abstract][Full Text] [Related]
10. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? File TM; Mandell LA Clin Infect Dis; 2003 Feb; 36(4):396-8. PubMed ID: 12567295 [No Abstract] [Full Text] [Related]
11. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269 [TBL] [Abstract][Full Text] [Related]
12. Bacteraemic pneumococcal pneumonia: current therapeutic options. Feldman C; Anderson R Drugs; 2011 Jan; 71(2):131-53. PubMed ID: 21275443 [TBL] [Abstract][Full Text] [Related]
13. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Lujan M; Gallego M; Fontanals D; Mariscal D; Rello J Crit Care Med; 2004 Mar; 32(3):625-31. PubMed ID: 15090938 [TBL] [Abstract][Full Text] [Related]
14. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Jacobs MR Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130 [No Abstract] [Full Text] [Related]
15. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Weiss K; Low DE; Cortes L; Beaupre A; Gauthier R; Gregoire P; Legare M; Nepveu F; Thibert D; Tremblay C; Tremblay J Can Respir J; 2004; 11(8):589-93. PubMed ID: 15611810 [TBL] [Abstract][Full Text] [Related]
18. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Martínez JA; Horcajada JP; Almela M; Marco F; Soriano A; García E; Marco MA; Torres A; Mensa J Clin Infect Dis; 2003 Feb; 36(4):389-95. PubMed ID: 12567294 [TBL] [Abstract][Full Text] [Related]
19. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Mufson MA; Chan G; Stanek RJ Am J Med Sci; 2007 Mar; 333(3):161-7. PubMed ID: 17496734 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Mongardon N; Max A; Bouglé A; Pène F; Lemiale V; Charpentier J; Cariou A; Chiche JD; Bedos JP; Mira JP Crit Care; 2012 Aug; 16(4):R155. PubMed ID: 22894879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]